Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma

• Endometrial mesonephric-like adenocarcinoma (MLA) is a rare and aggressive subtype of epithelial endometrial cancer. • KRAS mutations are characteristic in patients with endometrial MLA. • We report two cases of KRAS-mutated endometrial MLA with excellent and durable responses to lenvatinib and pe...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Sherry, Rubinstein, Maria M., Park, Kay J., Konner, Jason A., Makker, Vicky
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Reports and Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365456/
https://www.ncbi.nlm.nih.gov/pubmed/34430690
http://dx.doi.org/10.1016/j.gore.2021.100844
_version_ 1783738712071340032
author Shen, Sherry
Rubinstein, Maria M.
Park, Kay J.
Konner, Jason A.
Makker, Vicky
author_facet Shen, Sherry
Rubinstein, Maria M.
Park, Kay J.
Konner, Jason A.
Makker, Vicky
author_sort Shen, Sherry
collection PubMed
description • Endometrial mesonephric-like adenocarcinoma (MLA) is a rare and aggressive subtype of epithelial endometrial cancer. • KRAS mutations are characteristic in patients with endometrial MLA. • We report two cases of KRAS-mutated endometrial MLA with excellent and durable responses to lenvatinib and pembrolizumab. • Tumors with KRAS mutations may be particularly sensitive to lenvatinib, but this warrants further study.
format Online
Article
Text
id pubmed-8365456
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-83654562021-08-23 Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma Shen, Sherry Rubinstein, Maria M. Park, Kay J. Konner, Jason A. Makker, Vicky Gynecol Oncol Rep Case Reports and Case Series • Endometrial mesonephric-like adenocarcinoma (MLA) is a rare and aggressive subtype of epithelial endometrial cancer. • KRAS mutations are characteristic in patients with endometrial MLA. • We report two cases of KRAS-mutated endometrial MLA with excellent and durable responses to lenvatinib and pembrolizumab. • Tumors with KRAS mutations may be particularly sensitive to lenvatinib, but this warrants further study. Elsevier 2021-08-08 /pmc/articles/PMC8365456/ /pubmed/34430690 http://dx.doi.org/10.1016/j.gore.2021.100844 Text en © 2021 The Authors. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Reports and Case Series
Shen, Sherry
Rubinstein, Maria M.
Park, Kay J.
Konner, Jason A.
Makker, Vicky
Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma
title Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma
title_full Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma
title_fullStr Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma
title_full_unstemmed Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma
title_short Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma
title_sort sustained response to lenvatinib and pembrolizumab in two patients with kras-mutated endometrial mesonephric-like adenocarcinoma
topic Case Reports and Case Series
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8365456/
https://www.ncbi.nlm.nih.gov/pubmed/34430690
http://dx.doi.org/10.1016/j.gore.2021.100844
work_keys_str_mv AT shensherry sustainedresponsetolenvatinibandpembrolizumabintwopatientswithkrasmutatedendometrialmesonephriclikeadenocarcinoma
AT rubinsteinmariam sustainedresponsetolenvatinibandpembrolizumabintwopatientswithkrasmutatedendometrialmesonephriclikeadenocarcinoma
AT parkkayj sustainedresponsetolenvatinibandpembrolizumabintwopatientswithkrasmutatedendometrialmesonephriclikeadenocarcinoma
AT konnerjasona sustainedresponsetolenvatinibandpembrolizumabintwopatientswithkrasmutatedendometrialmesonephriclikeadenocarcinoma
AT makkervicky sustainedresponsetolenvatinibandpembrolizumabintwopatientswithkrasmutatedendometrialmesonephriclikeadenocarcinoma

Ejemplares similares